{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03484299",
            "orgStudyIdInfo": {
                "id": "17.0529"
            },
            "organization": {
                "fullName": "University of Louisville",
                "class": "OTHER"
            },
            "briefTitle": "Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma",
            "officialTitle": "Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "chemotherapy-and-irreversible-electroporation-in-the-treatment-of-advanced-pancreatic-adenocarcinoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-05-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-02-13",
            "studyFirstSubmitQcDate": "2018-03-23",
            "studyFirstPostDateStruct": {
                "date": "2018-03-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-16",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Robert C. Martin",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of Louisville"
            },
            "leadSponsor": {
                "name": "University of Louisville",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Compare the efficacy and tolerability of IRE in combination with either FOLFIRINOX or gemcitabine in patients with locally advanced pancreatic cancer.",
            "detailedDescription": "Phase II study in which all patients undergoing IRE for the treatment of locally advanced pancreatic carcinoma will receive either FOLFIRINOX or gemcitabine as peri-ablation treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Pancreas Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "All subjects undergoing IRE will receive treatment with either FOLFIRINOX or gemcitabine (based on which regimen was received prior to IRE)",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment",
                    "type": "OTHER",
                    "description": "Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)",
                    "interventionNames": [
                        "Procedure: Irreversible Electroporation (IRE)",
                        "Drug: Gemcitabine",
                        "Drug: FOLFIRINOX"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Irreversible Electroporation (IRE)",
                    "description": "Non-thermal ablation of tumor",
                    "armGroupLabels": [
                        "Treatment"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Gemcitabine",
                    "description": "25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled",
                    "armGroupLabels": [
                        "Treatment"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "FOLFIRINOX",
                    "description": "25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled",
                    "armGroupLabels": [
                        "Treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Adverse and Serious Adverse events will be captured (safety and tolerability)",
                    "description": "Adverse and Serious Adverse events will be collected and analyzed",
                    "timeFrame": "Time from first dose until subject has reached 90 days post last active study treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression free survival",
                    "description": "Triphase CT scan will be performed within one month of IRE procedure. Triphase CT scans will then be obtained every 3 months to check disease status.",
                    "timeFrame": "Time from first dose date to first date of confirmed disease progression, assessed for 90 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* greater than or equal to 18 years of age\n* diagnosed with stage III pancreatic cancer\n* tumor is measurable\n* GFR \\> mL/min/1.73m2\n* willing and able to comply with protocol requirements\n* AST/ALT \\>3 times upper limit of normal\n* stable surgical post-operative course as defined by operative surgeon\n\nExclusion Criteria:\n\n* participating in another clinical trial for the treatment of cancer at the time of screening\n* pregnant or currently breast feeding\n* have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure\n* have non-removable implants with metal parts within 1 cm of the target lesion\n* had a myocardial infarction within 3 months prior to enrollment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Traci Hayat, RN",
                    "role": "CONTACT",
                    "phone": "502-629-3383",
                    "email": "traci.hayat@louisville.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Robert Martin, MD, PhD",
                    "affiliation": "University of Louisville",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Louisville",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Traci Hayat, RN",
                            "role": "CONTACT",
                            "phone": "502-629-3383",
                            "email": "traci.hayat@louisville.edu"
                        },
                        {
                            "name": "Robert Martin, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "32681477",
                    "type": "DERIVED",
                    "citation": "Bhutiani N, Li Y, Zheng Q, Pandit H, Shi X, Chen Y, Yu Y, Pulliam ZR, Tan M, Martin RCG 2nd. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. Ann Surg Oncol. 2020 Oct;27(11):4348-4359. doi: 10.1245/s10434-020-08782-2. Epub 2020 Jul 17."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000010190",
                    "term": "Pancreatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010182",
                    "term": "Pancreatic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "asFound": "Adenocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "asFound": "Pancreas Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13102",
                    "name": "Pancreatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "C000627770",
                    "term": "Folfirinox"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M271136",
                    "name": "Folfirinox",
                    "asFound": "High Resolution",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}